Close Menu

Cancer Genetics Focus::Renal

Nov 02, 2016

Cancer Genetics has launched Focus::Renal, a next-generation sequencing panel for personalized medicine in renal cancers. The panel, developed in collaboration with leading cancer centers and academic institutions, is a comprehensive and accurate genomic profiling tool covering the majority of renal cancer markers and pathways. It detects mutations in 76 renal cancer-related genes, genome-wide copy number changes, and critical single nucleotide polymorphisms, enabling clinicians to diagnose, give a prognosis, and select therapies for renal cancer patients. Focus::Renal can also be used to distinguish among the dominant three malignant and one benign renal cancer subtypes.

More Like This

Aug 07, 2020

NIST: SARS-CoV-2 Synthetic Gene Fragments

Researchers at the National Institute of Standards and Technology have produced synthetic gene fragments from SARS-CoV-2. Shipped in vials with a data sheet listing the concentration of fragments in the solution, the RNA fragments can be used to measure the sensitivity of tests for the coronavirus. They can also use the synthetic RNA to develop more sensitive tests or new kinds of tests, NIST said. Each solution contains about 1 million copies per microliter. NIST is releasing the synthetic RNA as a research grade test material while it expects to further develop it as a standard reference material. The material is free to researchers, test manufacturers, and testing labs. Technical information and instructions for requesting the material are available here.

Aug 06, 2020

GeneDx GenomeXpress

GeneDx, a subsidiary of BioReference Laboratories/Opko Health, has launched GenomeXpress, a rapid genome sequencing test. GenomeXpress includes both protein-coding and non-coding regionsn of the genome including promoter, intronic, and untranslated regions, enabling the detection of characterized/pathogenic variants in regions that are not assessed by exome sequencing. The company delivers a written report for all confirmed variants in known disease-causing genes to the ordering healthcare provider within approximately seven days after testing. It also provides a written report for all confirmed variants within approximately 14 days after the start of testing. 

Aug 04, 2020

Horizon Discovery Single Cell RNAseq-Linked CRISPR Screening Service

Horizon Discovery has added single cell RNAseq-linked pooled CRISPR screening to its CRISPR screening services portfolio. Coupling pooled CRISPR screening to single cell RNAseq allows the impact of CRISPR-based gene modification to be examined on a global transcriptomic scale at single cell resolution. The platform offers high-quality screening data and biological insight to address gaps in target identification and validation by integrating the effect of gene editing with complex gene expression mapping, the company said. 

Aug 04, 2020

Adaptive Biotechnologies immunoSeq T-Map COVID service

Adaptive Biotechnologies has launched the immunoSeq T-Map COVID, a proprietary research product and data analysis service to measure the T cell immune response to vaccines in development and track the persistence of that response over time.

The product leverages data from over 1,000 patients to provide researchers with a quantitative map of T cell receptors and SARS-CoV-2 antigens that elicit an immune response. These data will be available through Adaptive's cloud-based immunoSeq Analyzer and is powered by ImmuneCode, an open database developed in partnership with Microsoft.

Aug 03, 2020

Cytek Biosciences cFluor Reagents

Flow cytometry firm Cytek Biosciences announced the launch cFluor reagents, short for "Cytek Fluorochrome," that are validated on the firm's Aurora and Northern Lights full spectrum cell analysis systems. The first batch of reagents includes cFluor YG584, cFluor B548, and cFluor R710 and allows users to reveal more from the full spectrum panel with a new option excitable by the yellow-green, blue, and red lasers respectively. Other dyes are coming soon, the firm said. 

Aug 03, 2020

Personalis NeXT Liquid Biopsy

Personalis has launched NeXT Liquid Biopsy, its plannd exome-scale blood-based tumor-profiling assay for advanced-stage solid tumor cancer patients. According to the company, the test monitors over twenty times more genes than most targeted liquid biopsy panels that have entered the market. Personalis believes its more comprehensive option can help biopharmaceutical companies advance their understanding of tumor biology, including resistance mechanisms, to aid the development of next-generation cancer therapies. 
Jul 31, 2020

Myriad Genetics Amplify for Fetal Cell-Free DNA Sequencing

Myriad Genetics has launched Amplify, which sequences the fetal cell-free DNA fragments circulating in a mother's blood and increases the fetal fraction in a sample for non-invasive prenatal screening. The company is hoping that the technology will improve the performance of its Prequel NIPS test. The analytical validation of Amplify involved samples from more than 1,000 women and showed that the fetal fraction was 2.3 times greater on average compared to standard NIPS. The improvement reduces false positive and false negative results, including for common aneuploidies, expanded aneuploidies, microdeletions, and a baby's sex, Myriad noted. The company also said that the technology will reduce the number of sampels that fail to produce a result due to low fetal fraction and deliver results to 99.9 percent of patients. 

Jul 30, 2020

Diagenode, Alithea Genomics Mercurius Bulk RNA Sequencing Services

Diagenode, a firm providing epigenomics services and library prep products, has announced a new bulk 3' mRNA sequencing service, developed in collaboration with Alithea Genomics.

The service incorporates Alithea's Mercurius barcoding for high-throughput transcriptomics and can be scaled for large study cohorts.

Jul 29, 2020

HTG Molecular Diagnostics HTG EdgeSeq Pan B-Cell Lymphoma Panel

HTG Molecular Diagnostics has launched its HTG EdgeSeq Pan B-Cell Lymphoma Panel, which the firm said is designed to provide molecular characteriation of aggressive, indolent, and rare lymphomas. The research-use-only panel enables investigators to measure the expression of about 300 genes linked to the lymphoma transcriptome. The panel is available in kit form or as a service at HTG's VERI/O laboratory. 

Jul 28, 2020

Twist Bioscience RUO SARS-CoV-2 Antibody Panels

Twist Bioscience is offering two new SARS-CoV-2 antibody panels for research use only.

The Twist anti-SARS-CoV-2 S1 antibody panel includes 32s human antibodies that bind with picomolar to nanomolar affinity to the S1 spike protein of the virus that causes COVID-19. The Human anti-ACE2 panel includes 48 antibodies that bind to the extracellular domain of the ACE2 receptor on human cells, the protein that facilitates entry of the coronavirus into cells.

All antibodies are cloned into human antibody backbones to generate VHH Fc, IgG1, or IgG2 antibodies. Individual antibodies within the panel can be licensed for further therapeutic or diagnostic development.

Jul 22, 2020

Twist Bioscience Synthetic Controls for Respiratory Viruses

Twist Bioscience has added 16 new synthetic controls for common respiratory viruses with symptoms similar to COVID-19, including influenza H1N1, influenza H32N, influenza B, rhinovirus, enterovirus, and several human coronaviruses including a prevalent mutated strain of SARS-CoV-2 (D614G.)

Applications for the products include environmental testing, assay development and verification, and diagnostic test validation.

Twist's controls are designed based on specific viral variants, cover the full viral genomes and are sequence-verified. Controls for alternative viral variants are available as custom products. The firm said RNA synthetic controls should be delivered within two weeks of ordering.

Jul 20, 2020

Bio-Techne miRNAscope Assay

Bio-Techne announced the expansion of its RNAscope platform in the form of the miRNAscope Assay. The miRNAscope Assay extends the firm's RNAscope technology to enable the in situ detection of short nucleic acid targets between 17 and 50 nucleotides, which includes microRNAs and short synthetic oligonucleotide therapeutics such as small interfering RNAs and antisense oligonucleotides.

Jul 17, 2020

Cepheid Xpert MTB/XDR

Cepheid has launched an assay to detect extensively drug-resistant tuberculosis. The CE-IVD marked Xpert MTB/XDR test uses new 10-color technology and runs on recalibrated GeneXpert instruments. It can be used to rapidly detect resistance to isoniazid, ethionamide, fluoroquinolones, amikacin, kanamycin, and capreomycin directly from patient specimens.

Jul 17, 2020

BioMérieux BioFire Mycoplasma

BioMérieux has launched BioFire Mycoplasma, an assay to detect mycoplasma bacteria in pharmaceutical products. The test is now available in the US, and will be launched in some countries in Europe and the Asia-Pacific region in the coming months.

Jul 16, 2020

RareCyte Orion Instrument

RareCyte has launched a new spatial biology analysis platform called Orion. The system is based on a patented and proprietary microscopy technology that allows comprehensive phenotypic profiling and spatial analysis of the tissue microenvironment at what the company claims are much faster speeds and with more efficiency than existing technologies.

The platform includes the Orion instrument and associated TissuePlex reagents. The instrument images an entire pathology slide at high speed and high resolution in 21 fluorescence channels. Companion TissuePlex panels are shipped as customizable catalog labelling kits. Customers can also access the technology through RareCyte laboratory services and other specified programs.

Public health experts call for a transparent COVID-19 vaccine approval process in a letter; the Food and Drug Administration commissioner assures science-based approval.

The Verge reports that new gene-naming guidelines aim in part to avoid Excel-related name change confusion.

In Nature this week: tuatara genome sequence aids in understanding amniote evolution, and more.

According to the Guardian, UK virologists say in a letter to officials that their expertise has been pushed aside in COVID-19 response plans.

Aug
18
Sponsored by
Bio-Rad

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Aug
24
Sponsored by
Genecentric

This webinar, Part 1 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss how gene expression signatures can accelerate (and rehabilitate) drug programs, define targeted patient populations, expand drug indications, and improve clinical success.

Aug
25
Sponsored by
Roche

Non-small cell lung cancer (NSCLC) patients with ALK rearrangements are treated with tyrosine kinase inhibitors (TKIs), which often leads to prolonged overall survival. However, treatment resistance will almost inevitably occur, and the disease remains incurable.

Aug
27
Sponsored by
Cellecta

Over 70 percent of breast cancers are estrogen receptor positive and are treated with endocrine therapy.